Division of Allergy and Immunology, Department of Internal Medicine.
Division of Allergy and Immunology, Department of Pediatrics, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.
Curr Opin Allergy Clin Immunol. 2021 Jun 1;21(3):263-268. doi: 10.1097/ACI.0000000000000739.
Despite the COVID-19 pandemic, progress continued in the field of peanut oral immunotherapy over the past 12 to 18 months. Of importance, the first oral immunotherapy product for the treatment of peanut allergy was approved by the US Food and Drug Administration in January 2020.
Suggested modifications to the practice of oral immunotherapy, some of which may have lasting impacts, were circulated as a result of the pandemic. New advances in pathophysiology, sustained unresponsiveness, quality of life, safety, and cost effectiveness were also published.
During 2020, COVID-19 influenced the daily practice of allergy and immunology, with peanut oral immunotherapy being no exception. However, clinicians now have a FDA-approved treatment option for peanut allergy in children, a welcome development for a difficult disease. Future research is needed to clarify several knowledge deficits surrounding the best use of peanut OIT.
目的综述：尽管 COVID-19 大流行，过去 12 至 18 个月内，花生口服免疫治疗领域仍取得了进展。重要的是，第一种用于治疗花生过敏的口服免疫治疗产品于 2020 年 1 月获得美国食品和药物管理局批准。
最近发现：由于大流行，免疫治疗实践中提出了一些建议性修改，其中一些可能会产生持久影响。在发病机制、持续无反应、生活质量、安全性和成本效益方面也取得了新的进展。
总结：2020 年，COVID-19 影响了过敏和免疫学的日常实践，花生口服免疫治疗也不例外。然而，临床医生现在有了一种 FDA 批准的儿童花生过敏治疗选择，这是对这种棘手疾病的一个可喜的发展。未来还需要研究来阐明围绕花生 OIT 的最佳使用的几个知识空白。
